Can Fite Biofarma (Can Fite Biofarma) EPS (Basic) : $-3.00 (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma EPS (Basic)?

Can Fite Biofarma's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-1.52. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.00.

Can Fite Biofarma's EPS (Diluted) for the three months ended in Dec. 2023 was $-1.52. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.00.

Can Fite Biofarma's EPS without NRI for the three months ended in Dec. 2023 was $-1.52. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -3.00.

During the past 3 years, the average EPS without NRI Growth Rate was 37.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 46.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 33.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Can Fite Biofarma's highest 3-Year average EPS without NRI Growth Rate was 58.70% per year. The lowest was -12.90% per year. And the median was 23.60% per year.

Can Fite Biofarma EPS (Basic) Historical Data

The historical data trend for Can Fite Biofarma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma EPS (Basic) Chart

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-42.00

-12.00

-9.00

-3.00

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-	-0.65	-0.40	-0.43	-1.52

Can Fite Biofarma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Can Fite Biofarma's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-7.634	-	0)	/	4.261
	=	-1.79

Can Fite Biofarma's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.652	-	0)	/	4.946
	=	-0.33

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.00

Can Fite Biofarma (AMEX:CANF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Can Fite Biofarma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).